Literature DB >> 35603733

Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma.

James Davis1, Mary McGann1, Abigail Shockley1, Hamza Hashmi1.   

Abstract

Entities:  

Keywords:  BCMA; CAR T; Myeloma; cilta-cel; ida-cel

Mesh：

Substances：

Year:  2022        PMID： 35603733     DOI： 10.1080/17474086.2022.2081147

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN： 1747-4094            Impact factor:   2.819


× No keyword cloud information.
  1 in total

1.  The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.

Authors:  Buthainah Ghanem; Lu Shi
Journal:  BioDrugs       Date:  2022-09-27       Impact factor: 7.744
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.